Cipher Pharmaceuticals I (DND.TO) 15.01 $DND.TO
Cipher Reports Financial Results for Q3 2014
CNW Group - Wed Oct 29, 6:00AM CDT
- Company also announces application to list on NASDAQ -
DND.TO: 15.01 (-0.01)
Notice of Cipher Pharmaceuticals Inc. Q3 2014 Conference Call
CNW Group - Mon Oct 20, 3:47PM CDT
Toronto Stock Exchange Symbol: DND
DND.TO: 15.01 (-0.01)
Ranbaxy Launches ABSORICA® (isotretinoin) 25 mg and 35 mg Capsules in the U.S. Market
PR Newswire - Wed Oct 01, 7:30AM CDT
Ranbaxy Laboratories Inc. (RLI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), today announced the launch of ABSORICA® (isotretinoin) 25 mg and 35 mg capsules into the U.S. healthcare market. ABSORICA has become the most prescribed branded oral isotretinoin in the U.S., as per a recent independent survey conducted with dermatologists. The product is licensed by Ranbaxy from Cipher Pharmaceuticals, Inc. It is indicated for the treatment of severe recalcitrant nodular acne in patients 12 years of age and older.
DND.TO: 15.01 (-0.01)
Cipher Pharmaceuticals Inc. to present at Rodman & Renshaw 16th Annual Global Investment Conference
CNW Group - Wed Sep 03, 6:00AM CDT
Cipher Pharmaceuticals Inc. (TSX: DND) ("Cipher" or "the Company"
today announced Shawn Patrick O'Brien, President and Chief Executive Officer, is presenting at the Rodman & Renshaw 16th Annual Global Investment Conference, which is being held in New York City from September 8-10 at the New York Palace Hotel. Mr. O'Brien will provide a corporate update and participate in a Q&A breakout session on Tuesday, September 9, 2014 at 9:35 AM ET in the Holmes 1 Salon.
DND.TO: 15.01 (-0.01)
Cipher reports financial results for Q2 2014
CNW Group - Wed Jul 30, 6:00AM CDT
Toronto Stock Exchange Symbol: DND
DND.TO: 15.01 (-0.01)
Cipher Pharmaceuticals and Ranbaxy Announce Distribution Agreement for Isotretinoin Product in Brazil
CNW Group - Thu Jul 24, 7:00AM CDT
Cipher Pharmaceuticals Inc. (TSX: DND) today announced it has entered into a definitive distribution and supply agreement with Ranbaxy Laboratories Ltd. ("Ranbaxy" under which Cipher has granted Ranbaxy the exclusive right to market, sell and distribute Cipher's isotretinoin capsules in Brazil. This agreement extends the current relationship with Ranbaxy, which markets and distributes Cipher's isotretinoin product in the United States under the brand Absorica(TM).
DND.TO: 15.01 (-0.01)
Cipher Pharmaceuticals appoints Shawn Patrick O'Brien as CEO
CNW Group - Thu Jun 26, 6:00AM CDT
Toronto Stock Exchange Symbol: DND
DND.TO: 15.01 (-0.01)
Cipher Pharmaceuticals completes distribution and supply agreement for isotretinoin product in Chile
CNW Group - Wed Jun 18, 6:00AM CDT
Toronto Stock Exchange Symbol: DND
DND.TO: 15.01 (-0.01)
Cipher appoints Thomas Wellner to Board
CNW Group - Tue Mar 25, 8:16AM CDT
Toronto Stock Exchange Symbol: DND
DND.TO: 15.01 (-0.01)
Cipher announces management change
CNW Group - Fri Mar 14, 6:00AM CDT
Toronto Stock Exchange Symbol: DND
DND.TO: 15.01 (-0.01)
Scanbuy Teams with GS1 Spain and GS1 Hungary to Offer Mobile Engagement Platform to Brands
Close-Up Media - Thu Feb 20, 11:32PM CST
Scanbuy, Inc. announced a partnership with GS1 Spain and GS1 Hungary to provide brands a mobile engagement platform that creates opportunities for real-world, real-time interaction with consumers via their mobile phones.
DND.TO: 15.01 (-0.01)
IIROC Trade Resumption - DND
CNW Group - Thu Sep 19, 9:59AM CDT
Trading resumes in:
DND.TO: 15.01 (-0.01)
Cipher's Partner Ranbaxy receives Paragraph IV Certification
CNW Group - Thu Sep 19, 9:45AM CDT
Toronto Stock Exchange Symbol: DND
DND.TO: 15.01 (-0.01)
IIROC Trading Halt - DND (all issues)
CNW Group - Thu Sep 19, 8:38AM CDT
The following issues have been halted by IIROC:
DND.TO: 15.01 (-0.01)
S&P Dow Jones Indices Announces Changes to the S&P/TSX Canadian Indices
CNW Group - Fri Sep 13, 4:15PM CDT
The Annual Review of the S&P/TSX SmallCap Index
ATP.TO: 2.35 (-0.04), ASR.TO: 2.18 (+0.12), CPX.TO: 26.58 (+0.27), LTS.TO: 2.80 (+0.04), AVO.TO: 18.02 (+0.33), CDI.TO: 5.47 (+0.02), CNE.TO: 3.82 (+0.15), FN.TO: 23.50 (+0.09), BLD.TO: 2.62 (-0.23), JE.TO: 5.74 (-0.03), BKX.TO: 0.47 (+0.01), HNL.TO: 3.23 (+0.06), RTK.TO: 2.69 (+0.01), DHX.TO: 8.75 (+0.27), KPT.TO: 16.23 (-0.17), AUQ.TO: 4.27 (+0.29), MM.TO: 0.46 (-0.04), CNL.TO: 2.01 (+0.18), CLC.TO: (), NFI.TO: 12.75 (-0.18), DND.TO: 15.01 (-0.01), ACQ.TO: 54.31 (+1.49), EPS.TO: 3.91 (+0.04)
Cipher reports record financial results for Q2 2013
CNW Group - Wed Jul 31, 6:00AM CDT
Revenue increases to $5.5 million; Company records earnings per share of $0.13
DND.TO: 15.01 (-0.01)
Cipher introduces Epuris(TM) (isotretinoin) capsules in Canadian market
CNW Group - Tue Jul 02, 7:30AM CDT
Toronto Stock Exchange Symbol: DND
DND.TO: 15.01 (-0.01)
Cipher Reports Financial Results for Q3 2014
CNW Group - Wed Oct 29, 6:00AM CDT
- Company also announces application to list on NASDAQ -
DND.TO: 15.01 (-0.01)
Notice of Cipher Pharmaceuticals Inc. Q3 2014 Conference Call
CNW Group - Mon Oct 20, 3:47PM CDT
Toronto Stock Exchange Symbol: DND
DND.TO: 15.01 (-0.01)
Ranbaxy Launches ABSORICA® (isotretinoin) 25 mg and 35 mg Capsules in the U.S. Market
PR Newswire - Wed Oct 01, 7:30AM CDT
Ranbaxy Laboratories Inc. (RLI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), today announced the launch of ABSORICA® (isotretinoin) 25 mg and 35 mg capsules into the U.S. healthcare market. ABSORICA has become the most prescribed branded oral isotretinoin in the U.S., as per a recent independent survey conducted with dermatologists. The product is licensed by Ranbaxy from Cipher Pharmaceuticals, Inc. It is indicated for the treatment of severe recalcitrant nodular acne in patients 12 years of age and older.
DND.TO: 15.01 (-0.01)
Cipher Pharmaceuticals Inc. to present at Rodman & Renshaw 16th Annual Global Investment Conference
CNW Group - Wed Sep 03, 6:00AM CDT
Cipher Pharmaceuticals Inc. (TSX: DND) ("Cipher" or "the Company"
today announced Shawn Patrick O'Brien, President and Chief Executive Officer, is presenting at the Rodman & Renshaw 16th Annual Global Investment Conference, which is being held in New York City from September 8-10 at the New York Palace Hotel. Mr. O'Brien will provide a corporate update and participate in a Q&A breakout session on Tuesday, September 9, 2014 at 9:35 AM ET in the Holmes 1 Salon. DND.TO: 15.01 (-0.01)
Cipher reports financial results for Q2 2014
CNW Group - Wed Jul 30, 6:00AM CDT
Toronto Stock Exchange Symbol: DND
DND.TO: 15.01 (-0.01)
Cipher Pharmaceuticals and Ranbaxy Announce Distribution Agreement for Isotretinoin Product in Brazil
CNW Group - Thu Jul 24, 7:00AM CDT
Cipher Pharmaceuticals Inc. (TSX: DND) today announced it has entered into a definitive distribution and supply agreement with Ranbaxy Laboratories Ltd. ("Ranbaxy"
under which Cipher has granted Ranbaxy the exclusive right to market, sell and distribute Cipher's isotretinoin capsules in Brazil. This agreement extends the current relationship with Ranbaxy, which markets and distributes Cipher's isotretinoin product in the United States under the brand Absorica(TM). DND.TO: 15.01 (-0.01)
Cipher Pharmaceuticals appoints Shawn Patrick O'Brien as CEO
CNW Group - Thu Jun 26, 6:00AM CDT
Toronto Stock Exchange Symbol: DND
DND.TO: 15.01 (-0.01)
Cipher Pharmaceuticals completes distribution and supply agreement for isotretinoin product in Chile
CNW Group - Wed Jun 18, 6:00AM CDT
Toronto Stock Exchange Symbol: DND
DND.TO: 15.01 (-0.01)
Cipher appoints Thomas Wellner to Board
CNW Group - Tue Mar 25, 8:16AM CDT
Toronto Stock Exchange Symbol: DND
DND.TO: 15.01 (-0.01)
Cipher announces management change
CNW Group - Fri Mar 14, 6:00AM CDT
Toronto Stock Exchange Symbol: DND
DND.TO: 15.01 (-0.01)
Scanbuy Teams with GS1 Spain and GS1 Hungary to Offer Mobile Engagement Platform to Brands
Close-Up Media - Thu Feb 20, 11:32PM CST
Scanbuy, Inc. announced a partnership with GS1 Spain and GS1 Hungary to provide brands a mobile engagement platform that creates opportunities for real-world, real-time interaction with consumers via their mobile phones.
DND.TO: 15.01 (-0.01)
IIROC Trade Resumption - DND
CNW Group - Thu Sep 19, 9:59AM CDT
Trading resumes in:
DND.TO: 15.01 (-0.01)
Cipher's Partner Ranbaxy receives Paragraph IV Certification
CNW Group - Thu Sep 19, 9:45AM CDT
Toronto Stock Exchange Symbol: DND
DND.TO: 15.01 (-0.01)
IIROC Trading Halt - DND (all issues)
CNW Group - Thu Sep 19, 8:38AM CDT
The following issues have been halted by IIROC:
DND.TO: 15.01 (-0.01)
S&P Dow Jones Indices Announces Changes to the S&P/TSX Canadian Indices
CNW Group - Fri Sep 13, 4:15PM CDT
The Annual Review of the S&P/TSX SmallCap Index
ATP.TO: 2.35 (-0.04), ASR.TO: 2.18 (+0.12), CPX.TO: 26.58 (+0.27), LTS.TO: 2.80 (+0.04), AVO.TO: 18.02 (+0.33), CDI.TO: 5.47 (+0.02), CNE.TO: 3.82 (+0.15), FN.TO: 23.50 (+0.09), BLD.TO: 2.62 (-0.23), JE.TO: 5.74 (-0.03), BKX.TO: 0.47 (+0.01), HNL.TO: 3.23 (+0.06), RTK.TO: 2.69 (+0.01), DHX.TO: 8.75 (+0.27), KPT.TO: 16.23 (-0.17), AUQ.TO: 4.27 (+0.29), MM.TO: 0.46 (-0.04), CNL.TO: 2.01 (+0.18), CLC.TO: (), NFI.TO: 12.75 (-0.18), DND.TO: 15.01 (-0.01), ACQ.TO: 54.31 (+1.49), EPS.TO: 3.91 (+0.04)
Cipher reports record financial results for Q2 2013
CNW Group - Wed Jul 31, 6:00AM CDT
Revenue increases to $5.5 million; Company records earnings per share of $0.13
DND.TO: 15.01 (-0.01)
Cipher introduces Epuris(TM) (isotretinoin) capsules in Canadian market
CNW Group - Tue Jul 02, 7:30AM CDT
Toronto Stock Exchange Symbol: DND
DND.TO: 15.01 (-0.01)
